Alumis Stock Plummets 55% After Lupus Drug Trial Failure
By Business Desk
Alumis shares crashed over 55% after its Phase 2b trial for lupus drug envudeucitinib missed primary and secondary endpoints, impacting investor confidence.
US-based biopharmaceutical firm Alumis experienced a significant plunge in its shares, dropping over 55% on Tuesday. This sharp decline followed the announcement that its Phase 2b LUMUS trial for envudeucitinib, a drug targeting moderate-to-severe lupus erythematosus, failed to meet both its primary and secondary endpoints in the overall trial population.
- Stock Performance: Alumis shares tumbled by as much as 56%.
- Trading Price: The stock reached $9.59 per share shortly after the market’s opening bell.
The trial’s inability to achieve its set objectives signals a major setback for the treatment in its broader application. This outcome directly impacted investor sentiment, triggering the substantial share price drop observed during early trading hours.
Trial Findings and Regulatory Outlook
Despite the overall failure of the LUMUS trial, Dr. Jörn Drappa, Chief Medical Officer of Alumis, highlighted a “highly compelling” effect. This specific positive response was noted within a prespecified IFNGS-high subgroup, presenting a potential area for further exploration.
Alumis has confirmed its intention to initiate discussions with regulatory bodies regarding the future path for Phase 3 development of envudeucitinib. The company remains focused on addressing the critical need for targeted oral therapies for lupus erythematosus, a medical area currently lacking such options.